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Abstract 
BACKGROUND: Previous studies demonstrated the promising value of platelet-to-lymphocyte (PLR) in prostate 
cancer. 
AIM: This study was conducted to evaluate its pre-biopsy values in predicting prostate cancer. 
METHODS: We included all benign prostatic hyperplasia (BPH) and prostate cancer (PCa) patients who 
underwent a prostate biopsy in Adam Malik Hospital between August 11th 2011 and August 31st 2015. The 
relationship between pre-biopsy variables which could be affecting the percentage of prostate cancer risk was 
evaluated, including age, prostate-specific antigen (PSA) level, and prostate volume (EPV). The PLR was 
calculated from the ratio of related platelets with their absolute lymphocyte counts. The values then analysed to 
evaluate their associations with the diagnosis of BPH and PCa. 
RESULTS: As many as 298 patients consisted of 126 (42.3%) BPH and 172 PCa (57.7%) patients are included in 
this study. Mean age for both groups are 66.36 ± 7.53 and 67.99 ± 7.48 years old (p = 0.64), respectively. There 
are statistically significant differences noted from PSA (19.28 ± 27.11 vs 40.19 ± 49.39), EPV (49.39 ± 23.51 vs 
58.10 ± 30.54), PLR (160.27 ± 98.96 vs 169.55 ± 78.07), and NLR (3.57 ± 3.23 vs 4.22 ± 2.59) features of both 
groups (p < 0.05). The AUC of PLR is 57.9% with a sensitivity of 56.4% and specificity of 55.6% in the cut-off 
point of 143 (p = 0.02). Besides, the NLR cut-off point of 3.08 gives 62.8% AUC with 64.5% sensitivity and 63.5% 
specificity. We asked for permission from the preceding authors of Indonesian Prostate Cancer Risk Calculator 
(IPCRC) and calculated its value from 98 randomised patients consist of 45 (45.92%) BPH and 53 (54.08%) PCa. 
We found a comparable value between PLR/NLR with IPCRC in predicting prostate cancer (AUC of 67.6%, 
75.3%, and 68.4%, respectively) with a statistically significant difference of all value in both groups (p < 0.05). 
CONCLUSIONS: PLR gives promising value in predicting prostate cancer in suspected patients. We suggest a 
further prospective study to validate its diagnostic values so it can be used as applicable routine calculation. 
 
 
 
 
 
 
Introduction 
 
Prostate cancer (PCa) is the second most 
common cancer worldwide. It accounts for more than 
15% of cancer in men, its clinical relevance keeps 
rising, and 70% of them occurs in developed countries 
[1], [2]. Prostate biopsy is required for the 
histopathological diagnosis of prostate cancer, and 
Trans Rectal Ultrasound Guided procedure remains 
the gold standard in most countries. Since the biopsy 
is mostly office procedure and associated with 
significant complications, various non-invasive 
strategies have been invented to prevent unnecessary 
biopsy.  
Serum Prostate Specific Antigen (PSA) has 
been used as the screening standard for patients in 
suspicion of prostate cancer. In most countries, PSA 
value of more than 4 ng/ml has been the standard 
threshold to perform prostate biopsy [1], [2], [3], [4], 
[5], [6], [7]. But, recent meta-analyses showed that in 
patients with PSA levels over 4 ng/ml, the positive 
predictive value of PSA is only 25% [5]. Also, the 
invasive prostate biopsy may still miss some 
percentage of cancer, given that up to 20% of men will 
have prostate cancer in a repeated biopsy [8]. Various 
imaging and biomolecular marker have been 
suggested to increase diagnostic accuracy, but none 
of these methods is available for widespread use, 
either due to availability issues or the high cost [2], [8]. 
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Over the past decades, our study of the 
microenvironment of cancer has supported Virchow’s 
hypothesis of the connection between inflammation 
and cancer. Inflammatory markers have been 
associated with more aggressive disease [6], [9]. 
Though small in numbers, previous studies 
demonstrated a promising value of platelet-to-
lymphocyte (PLR) in prostate cancer. Kaynar et al. 
found an increased level of PLR in PCa compared 
with that in benign prostatic hyperplasia (BPH) with 
PSA value greater than 10 ng/ml [10]. A statistically 
significant higher value of PLR in PCa compared to 
BPH patients was also demonstrated by Yuksel et al., 
in 2015 [5]. According to our knowledge, there is still 
no data on the use of PLR value as a predictor of PCa 
in Indonesia.  
Therefore, this study is conducted to evaluate 
its pre-biopsy value in predicting PCa.  
 
 
Material and Methods 
 
Population of Study 
This is a diagnostic study with a retrospective 
design. All patients who underwent a prostate biopsy 
in Adam Malik General Hospital between August 2011 
and August 2015 were included. Data related to 
prostate cancer prediction factors were collected, and 
their relationship with malignant pathology was 
analysed. The factors included were: age, serum PSA 
value, and estimated prostate volume (EPV). The PLR 
values were calculated using the routine blood count 
results, collected right before the biopsy procedures 
were performed. Histopathology of the biopsy 
specimen was applied as the gold standard of PCa 
diagnosis. Patients with irrelevant and incomplete 
data were excluded from the study. 
 
Variables 
Serum PSA was collected from recent 
laboratory results just before biopsy procedures were 
performed. We collected EPVs from their initial 
prostatic Trans Abdominal ultrasound (TAUS) data. 
Prostate was measured in 3-dimensional aspects, and 
its volume was estimated with the modified ellipsoid 
formulation in cm
3
 (0.523 [(length x width x height)]. 
PLR value is a direct ratio of platelets and absolute 
lymphocyte count which was acquired from the routine 
blood count at initial assessment. 
 
Analysis 
Data input and analyses were performed 
using SPSS ver 20.0 software. Data will be divided 
into two groups according to their histopathology of 
prostate biopsy, the BPH and PCa group. Data related 
to PCa prediction such as routine blood count and 
PLR of each group will be distributed in frequency 
table and analysed for their value in predicting biopsy 
results with bivariate analysis. A p value of < 0.05 ( = 
5%) was considered statistically significant.  
 
 
Results 
 
Characteristics and Bivariate Analysis 
As many as 298 patients consisted of 126 
(42.3%) BPH and 172 PCa (57.7%) patients are 
included in this study. Mean age for both groups are 
66.36 ± 7.53 and 67.99 ± 7.48 years old (p = 0.64), 
respectively. Patient’s characteristics and laboratory 
values are shown in Table 1. 
Table 1: Patients Characteristics and Hematologic Parameters 
Parameters BPH (n = 126) 
Mean ± SD 
(Median) 
PCa (n = 172) 
Mean ± SD 
(Median) 
p 
Age (years) 66.36 ± 7.53 67.99 ± 7.48 0.64* 
PSA (ng/dL) 19.28 ± 27.11 40.19 ± 49.39 < 0.0001* 
EPV (cm
3
) 49.39 ± 23.51 58.10 ± 30.54 0.02* 
Hb 12.99 ± 2.00 (13.20) 12.95 ± 2.01 (13.10) 0.754** 
Leucocytes Count (x 10
3
/mm
3
) 8.67 ± 3.45 (8.11) 9.19 ± 3.29 (8.46) 0.1** 
Absolute Lymphocyte Count (x 
10
3
/mm
3
) 
2.09 ± 0.83 (2.02) 2.00 ± 0.76 (1.87) 0.29** 
Platelets Count (x 10
3
/mm
3
) 286.16 ± 112.24 (266) 311.61 ± 120.81 
(294) 
0.049** 
PLR 160.27 ± 98.96 
(128.13) 
169.55 ± 78.07 
(151.28) 
0.02** 
*T-test **Mann-Whitney Test 
 
Comparing the laboratory results of both 
groups, statistically, significant differences were noted 
from PSA (19.28 ± 27.11 vs 40.19 ± 49.39), EPV 
(49.39 ± 23.51 vs 58.10 ± 30.54), and PLR (160.27 ± 
98.96 vs 169.55 ± 78.07) in each bivariate analysis. 
 
PLR and PSA 
We then performed a Receiver Operating 
Characteristics (ROC) analysis to define the Area 
under Curve (AUC) of PLR in predicting prostate 
cancer (Figure 1 and Table 2).  
 
Figure 1: The ROC Curves of PLR and PSA  
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The AUC of PLR is 57.9% with a sensitivity of 
56.4% and specificity of 55.6% in the cut-off point of 
143 (p = 0.02). 
Table 2: The AUC of PLR and PSA 
Parameters AUC p 
PLR 57.9% 0.02 
PSA 68.5% < 0.0001 
 
 
PLR and IPCRC 
We asked for permission from the preceding 
authors of Indonesian Prostate Cancer Risk 
Calculator (IPCRC) and calculated its value from 98 
randomised patients which consist of 45 (45.92%) 
BPH and 53 (54.08%) PCa.  
 
Figure 2: The ROC Curves of PLR and IPCRC Score 
 
We found a comparable value between PLR 
with IPCRC in predicting prostate cancer (AUC of 
67.6% and 68.4%, respectively) with a statistically 
significant difference was noted between each value 
(p < 0.05) as shown in Figure 2 and Table 2. 
Table 2: The AUC of PLR and IPCRC 
Parameters AUC p 
PLR 67.6% 0.003 
IPCRC 68.5% 0.002 
 
 
 
 
Discussion 
 
The body response to cancer parallels with 
inflammation and wound healings. In 1863, Rudolf 
Virchow noted leucocytes in neoplastic tissues and 
suggested a connection between inflammation and 
cancer. He suggested that the “lymphoreticular 
infiltration” reflected the origin of cancer at sites of 
chronic inflammation. Tumour-infiltrating lymphocytes 
may contribute to cancer growth and spread, and the 
immunosuppression-associated malignant diseases. 
In his review in 2001, Balkwill et al. still mentioned the 
theory of “Tumors: wounds that do not heal” 
previously showed by Dvorak in 1986. This theory 
showed how wound healing and tumour stroma 
formation share many important features. Wound 
healing is usually self-limiting, but tumours secrete a 
vascular permeability factor, vascular endothelial 
growth factor (VEGF), that can lead to persistent 
extravasation of fibrin and fibronectin and continuous 
regeneration of extracellular matrix. Platelets in 
wounds are critical sources of cytokines, especially for 
transforming growth factor  (TGF-) and VEGF. 
Platelet release may also play an important role in 
angiogenesis. Also, malignant cells secrete 
proinflammatory cytokines independently [9]. This will 
be the basis of predicting cancer through platelets 
count [6], [9]. Our study found a significant difference 
between platelet counts of PCa and benign prostatic 
lesions (311.61 ± 120.81 vs 286.16 ± 112.24; 
p=0.049) which supported the previous theory. But, a 
previous larger sample study from Yuksel et al., did 
not show the same results (p = 0.094) [5]. From these 
findings, we concluded that platelet count could not 
stand alone as the only predictive marker. 
Though inflammatory markers such as 
lymphocytes were mentioned in previous studies, not 
all markers are coherent with every cancer. 
Leucocytes, mainly lymphocytes, are the most 
prominent marker in many cancers, but not in PCa. 
Study of Cihan Y, et al. showed that patients with PCa 
had a lower level of lymphocytes, neutrophils, and a 
higher level of monocytes with a significant difference 
in lymphocyte count, compared to healthy controls 
[11]. McDonald et al., also found that lymphocytes 
count is significantly lower in patients with elevated 
PSA compared with patients with PSA below 4 ng/ml 
[3]. Though this study found that the absolute 
lymphocyte counts of PCa patients are lower, the 
difference was not statistically significant compared 
with a benign group (2.09 ± 0.83 vs 2.00 ± 0.76; p = 
0.23). 
In this study, though we found a significant 
difference of platelets count with no statistical 
difference in lymphocyte count between both groups, 
the ratio of PLR value gives the event more significant 
difference (p = 0.02). A similar result was also shown 
by Yuksel et al., where a significant intergroup 
statistical difference was found for PLR (p = 0.041) but 
not for lymphocyte count (p > 0.05) [5]. This also 
supported by the study of Li et al., who found a 
statistical difference between PCa and normal/BPH 
patient (p < 0.05). Kaynar et al., also found that 
statistically significant value of PLR was observed in 
PCa and BPH patients with PSA above 10 ng/ml [10]. 
Yuksel et al. found a statistically significant 
difference of PLR value between PCa and BPH 
patients, but not between PCa and prostatitis (p = 
0.018 vs p = 0.067). This could be related to the 
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previous theory of “Tumors: wounds that do not heal” 
[9]. According to this theory, inflammation cascade, 
which always happens in the inflammation process, is 
also continuously happening in tumours without 
receding. In this study, we put aside the prostatic non-
BPH benign lesions to selectively reduce this bias. So 
we merely compared the histopathologically proven 
BPH and PCa patients. However, this can only 
happen in the study with the retrospective design. In 
the case of prospective design, we cannot conclude 
whether the prediction of PCa through PLR value can 
differentiate the histopathology of PCa and prostatitis. 
Further prospective studies, as well as more 
predictive marker, are needed.  
In conclusion, inflammation cascade, which 
always happens in the inflammation process, is also 
continuously happening in tumours without receding. 
PLR gives promising value as a systemic 
inflammatory marker in predicting prostate cancer in 
suspected patients. And in this study, we tried to 
investigate the applicability in Indonesia. But, if to be 
applied as routine testing and to selectively decide 
candidates for prostate biopsy in a patient with PSA 
value more than 4 ng/ml, this value needs a further 
prospective trial. 
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